Wayne Kuznar

Articles

Acalabrutinib Regimen Highly Active in MCL

December 13th 2018

Adding the BTK inhibitor acalabrutinib to bendamustine and rituximab induced high overall response rates in both treatment-naive and relapsed/refractory patients with mantle cell lymphoma.

BiTE Antibodies Show Encouraging Activity in Myeloma, AML

December 11th 2018

Data from 2 early-stage trials of bispecific T-cell engager antibody constructs in relapsed/refractory hematologic malignancies demonstrated antitumor activity and early evidence of tolerability.

Selinexor Promotes Deep, Durable Responses in Relapsed/Refractory DLBCL

December 11th 2018

Selinexor monotherapy induced deep and durable responses in the phase IIb SADAL study of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

ACE Inhibitor, Beta Blocker Lower Trastuzumab Cardiotoxicity Risk in HER2+ Breast Cancer

December 10th 2018

In patients with early-stage HER2-positive breast cancer who are being treated with adjuvant trastuzumab and anthracyclines, cardiotoxicity-free survival is longer when they receive prophylactic simultaneous lisinopril or carvedilol.

CAR T-Cell Therapy Shows Early Potential in TNBC

December 8th 2018

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer

December 8th 2018

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer

December 7th 2018

Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.

Extended PFS Observed in Alpelisib Combo for PIK3CA-Mutant Breast Cancer

December 7th 2018

Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.

Myelopreservation Possible With CDK4/6 Inhibitor Trilaciclib in TNBC

December 7th 2018

A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.

PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC

December 6th 2018

Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.

Mutation in BCL2 Protein Confers Resistance to Venetoclax

December 4th 2018

A newly discovered recurrent mutation in the B-cell leukemia/lymphoma 2 protein mediates clinical resistance to venetoclax in patients with chronic lymphocytic leukemia.

Selinexor Induces Responses in a Quarter of Patients with Heavily Pretreated MM

December 4th 2018

A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.

Acalabrutinib Monotherapy Produces Durable Response in Mantle Cell Lymphoma

December 4th 2018

Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.

Ibrutinib/Venetoclax Combination Achieves High Rate of MRD Negativity in Relapsed/Refractory CLL

December 3rd 2018

The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Highly Active in Relapsed/Refractory MCL

December 2nd 2018

The investigational agent zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, is highly active in patients with relapsed/refractory mantle cell lymphoma.

Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM

December 2nd 2018

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

Pegylated Doxorubicin/Carboplatin Plus Bevacizumab Improves PFS in Recurrent Ovarian Cancer

November 14th 2018

The combination regimen of pegylated liposomal doxorubicin with bevacizumab was found to significantly improve progression-free survival versus carboplatin/gemcitabine in select patients with recurrent ovarian cancer.

Long-Term Maintenance Olaparib Safe and Effective for Patients With Recurrent Ovarian Cancer

November 14th 2018

Long-term maintenance therapy with olaparib (Lynparza) tablets demonstrated a low rate of treatment discontinuation and tolerable safety profile in patients with platinum-sensitive recurrent ovarian cancer.

Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer

November 12th 2018

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

Real-World Data With Niraparib Show Lower AEs Vs ENGOT-OV6/NOVA Trial in Ovarian Cancer

November 8th 2018

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.